Avadel Pharmaceuticals plc (AVDL)
Largest Insider Buys in Sector
AVDL Stock Price History Chart
AVDL Stock Performance
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Insider Activity of Avadel Pharmaceuticals plc
Over the last 12 months, insiders at Avadel Pharmaceuticals plc have bought $29,000 and sold $1.09M worth of Avadel Pharmaceuticals plc stock.
On average, over the past 5 years, insiders at Avadel Pharmaceuticals plc have bought $846,568 and sold $514,858 worth of stock each year.
Highest buying activity among insiders over the last 12 months: MCHUGH THOMAS S (Chief Financial Officer) — $29,000.
The last purchase of 2,000 shares for transaction amount of $29,000 was made by MCHUGH THOMAS S (Chief Financial Officer) on 2024‑01‑16.
List of Insider Buy and Sell Transactions, Avadel Pharmaceuticals plc
| 2024-01-16 | Chief Financial Officer | 2,000 0.0021% | $14.50 | $29,000 | +5.27% | |||
| 2023-12-28 | Sale | director | 75,000 0.0802% | $14.53 | $1.09M | +6.03% | ||
| 2023-08-14 | Chief Financial Officer | 2,000 0.0027% | $14.45 | $28,900 | +3.32% | |||
| 2023-08-11 | Sale | director | 28,975 0.0388% | $14.93 | $432,614 | -1.05% | ||
| 2023-08-10 | Chief Executive Officer | 10,000 0.0128% | $13.20 | $131,997 | +7.26% | |||
| 2023-08-10 | director | 14,000 0.0182% | $13.40 | $187,600 | +7.26% | |||
| 2023-05-18 | director | 13,000 0.0207% | $13.93 | $181,100 | +2.60% | |||
| 2023-05-09 | director | 2,500 0.0038% | $14.76 | $36,900 | -6.72% | |||
| 2022-12-23 | director | 2,000 0.0033% | $7.20 | $14,405 | +61.03% | |||
| 2022-11-29 | Chief Financial Officer | 5,000 0.008% | $7.80 | $39,000 | +36.61% | |||
| 2022-11-22 | director | 20,000 0.0314% | $7.80 | $156,050 | +32.02% | |||
| 2022-06-01 | 45,000 0.068% | $2.14 | $96,300 | +191.25% | ||||
| 2022-05-31 | 20,000 0.0349% | $2.27 | $45,496 | +216.29% | ||||
| 2022-05-31 | director | 45,000 0.0738% | $2.14 | $96,300 | +216.29% | |||
| 2022-05-27 | Chief Executive Officer | 50,000 0.0694% | $2.05 | $102,500 | +179.00% | |||
| 2022-05-27 | 15,000 0.0249% | $2.45 | $36,747 | +179.00% | ||||
| 2022-05-27 | 50,000 0.0573% | $1.69 | $84,500 | +179.00% | ||||
| 2022-05-27 | Chief Financial Officer | 50,000 0.0724% | $2.14 | $106,895 | +179.00% | |||
| 2022-05-27 | 10,000 0.0108% | $1.60 | $16,000 | +179.00% | ||||
| 2020-09-18 | Chief Financial Officer | 4,000 0.007% | $6.00 | $24,000 | +28.91% |
Insider Historical Profitability
| MCHUGH THOMAS S | Chief Financial Officer | 80500 0.0836% | $15.27 | 7 | 0 | +48.83% |
| McCamish Mark Anthony | director | 67025 0.0696% | $15.27 | 2 | 2 | +28.91% |
| STAPLETON CRAIG R | director | 323413 0.3359% | $15.27 | 12 | 1 | <0.0001% |
| ANDERSON MICHAEL S | Chief Executive Officer | 248953 0.2586% | $15.27 | 11 | 1 | <0.0001% |
| Ende Eric J | director | 167900 0.1744% | $15.27 | 9 | 0 | +59% |
Institutional Investor Ownership
| Janus Henderson | $218.18M | 13.44 | 12.92M | +16.09% | +$30.24M | 0.11 | |
| RTW Investments, LP | $148.61M | 9.15 | 8.8M | +26.64% | +$31.26M | 2.23 | |
| Polar Capital | $114.07M | 7.03 | 6.75M | +0.03% | +$31,922.10 | 0.63 | |
| Vivo Capital | $67.09M | 4.13 | 3.97M | -3.04% | -$2.1M | 5.84 | |
| Braidwell Lp | $45.07M | 2.78 | 2.67M | New | +$45.07M | 2.55 |